By Fineline Cube Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round, led by OrbiMed with participation from TCG Crossover, Lilly Asia Ventures (LAV), Centurium Capital, and existing shareholders Shenzhen Capital Group (SCGC) and Oriza Holdings. The funding will accelerate the company’s lead asset, AC-101, a global-leading RIPK2 inhibitor, into a Phase IIb clinical trial for ulcerative colitis (UC), while advancing multiple pipeline candidates for inflammatory and immune diseases.
Financing Details & Investor Syndicate
| Component | Details |
|---|---|
| Round | Series C |
| Amount Raised | $50 million |
| Lead Investor | OrbiMed |
| New Investors | TCG Crossover, Lilly Asia Ventures (LAV), Centurium Capital |
| Existing Investors | Shenzhen Capital Group (SCGC), Oriza Holdings |
| Strategic Significance | Strong validation from both global healthcare specialists (OrbiMed, LAV) and crossover investors |
Lead Asset: AC-101 Clinical Development
AC-101 represents a novel, selective RIPK2 inhibitor developed from Accro’s proprietary drug discovery platform targeting regulated cell death pathways:
- Mechanism: Selective inhibition of Receptor-interacting protein kinase 2 (RIPK2), a key mediator of the NOD signaling pathway
- Therapeutic Rationale: Dysregulation of the NOD–RIPK2 pathway is implicated in various autoimmune diseases, particularly inflammatory bowel disease (IBD)
- Clinical Progress:
- Phase I trials completed in Australia and China with favorable safety profile and strong PK/PD data
- Phase Ib/IIa proof-of-concept trial completed in Chinese patients with moderate-to-severe UC
- US regulatory clearance obtained for Phase II clinical study in ulcerative colitis
- Next Milestone: Phase IIb global trial initiation expected in Q3 2026
Pipeline Expansion Strategy
Beyond AC-101, the financing will support development of multiple additional pipeline assets targeting inflammatory and immune diseases, leveraging Accro’s proprietary platform for regulated cell death modulation. This diversified approach reduces single-asset risk while capitalizing on validated target biology.
Market Opportunity & Competitive Landscape
- Ulcerative Colitis Market: Global UC therapeutics market projected to reach $12.8 billion by 2030, with significant unmet need for safer, more effective oral therapies
- RIPK2 Target Validation: Emerging as a high-priority target in IBD, with multiple pharma companies pursuing RIPK2 inhibitors but Accro positioned as potential first-to-market
- Differentiation Advantage: AC-101’s selectivity profile may offer improved safety compared to broader kinase inhibitors, addressing key limitations of current UC therapies
- China Innovation Ecosystem: Accro exemplifies the maturation of China’s biotech sector, with domestic innovation achieving global competitive positioning in specialized therapeutic areas
Strategic Investor Alignment
The investor consortium brings complementary strategic value:
- OrbiMed: Global healthcare expertise and regulatory guidance for US/EU development
- Lilly Asia Ventures: Potential partnership opportunities with Eli Lilly’s immunology franchise
- TCG Crossover: Public market preparation and valuation expertise
- Chinese Institutional Investors: Local market access and operational support
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market opportunities for AC-101 and Accro’s pipeline. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption patterns.-Fineline Info & Tech